85 related articles for article (PubMed ID: 30560565)
1. Antitumor effect of palmitic acid-conjugated DsiRNA for colon cancer in a mouse subcutaneous tumor model.
Kubo T; Nishimura Y; Hatori Y; Akagi R; Mihara K; Yanagihara K; Seyama T
Chem Biol Drug Des; 2019 Apr; 93(4):570-581. PubMed ID: 30560565
[TBL] [Abstract][Full Text] [Related]
2. Amino-modified and lipid-conjugated dicer-substrate siRNA enhances RNAi efficacy.
Kubo T; Takei Y; Mihara K; Yanagihara K; Seyama T
Bioconjug Chem; 2012 Feb; 23(2):164-73. PubMed ID: 22236254
[TBL] [Abstract][Full Text] [Related]
3. In Vivo RNAi Efficacy of Palmitic Acid-Conjugated Dicer-Substrate siRNA in a Subcutaneous Tumor Mouse Model.
Kubo T; Yanagihara K; Seyama T
Chem Biol Drug Des; 2016 Jun; 87(6):811-23. PubMed ID: 26800111
[TBL] [Abstract][Full Text] [Related]
4. Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin.
Ganesh S; Koser ML; Cyr WA; Chopda GR; Tao J; Shui X; Ying B; Chen D; Pandya P; Chipumuro E; Siddiquee Z; Craig K; Lai C; Dudek H; Monga SP; Wang W; Brown BD; Abrams MT
Mol Cancer Ther; 2016 Sep; 15(9):2143-54. PubMed ID: 27390343
[TBL] [Abstract][Full Text] [Related]
5. Lipid-conjugated 27-nucleotide double-stranded RNAs with dicer-substrate potency enhance RNAi-mediated gene silencing.
Kubo T; Yanagihara K; Takei Y; Mihara K; Sato Y; Seyama T
Mol Pharm; 2012 May; 9(5):1374-83. PubMed ID: 22494497
[TBL] [Abstract][Full Text] [Related]
6. Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer.
Ye Z; Abdelmoaty MM; Ambardekar VV; Curran SM; Dyavar SR; Arnold LL; Cohen SM; Kumar D; Alnouti Y; Coulter DW; Singh RK; Vetro JA
Nanomedicine; 2021 Apr; 33():102363. PubMed ID: 33545405
[TBL] [Abstract][Full Text] [Related]
7. Gene-silencing potency of symmetric and asymmetric lipid-conjugated siRNAs and its correlation with dicer recognition.
Kubo T; Yanagihara K; Sato Y; Nishimura Y; Kondo S; Seyama T
Bioconjug Chem; 2013 Dec; 24(12):2045-57. PubMed ID: 24274056
[TBL] [Abstract][Full Text] [Related]
8. Complexation of Chol-DsiRNA in place of Chol-siRNA greatly increases the duration of mRNA suppression by polyplexes of PLL(30)-PEG(5K) in primary murine syngeneic breast tumors after i.v. administration.
Ambardekar VV; Wakaskar RR; Ye Z; Curran SM; McGuire TR; Coulter DW; Singh RK; Vetro JA
Int J Pharm; 2018 May; 543(1-2):130-138. PubMed ID: 29601972
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo.
Dudek H; Wong DH; Arvan R; Shah A; Wortham K; Ying B; Diwanji R; Zhou W; Holmes B; Yang H; Cyr WA; Zhou Y; Shah A; Farkiwala R; Lee M; Li Y; Rettig GR; Collingwood MA; Basu SK; Behlke MA; Brown BD
Mol Ther; 2014 Jan; 22(1):92-101. PubMed ID: 24089139
[TBL] [Abstract][Full Text] [Related]
10. Palmitic acid-conjugated 21-nucleotide siRNA enhances gene-silencing activity.
Kubo T; Yanagihara K; Takei Y; Mihara K; Morita Y; Seyama T
Mol Pharm; 2011 Dec; 8(6):2193-203. PubMed ID: 21985606
[TBL] [Abstract][Full Text] [Related]
11. Dicer-labile PEG conjugates for siRNA delivery.
Kow SC; McCarroll J; Valade D; Boyer C; Dwarte T; Davis TP; Kavallaris M; Bulmus V
Biomacromolecules; 2011 Dec; 12(12):4301-10. PubMed ID: 22053777
[TBL] [Abstract][Full Text] [Related]
12. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
13. Gene silencing of beta-catenin by RNAi inhibits cell proliferation in human esophageal cancer cells in vitro and in nude mice.
Wang JS; Zheng CL; Wang YJ; Wen JF; Ren HZ; Liu Y; Jiang HY
Dis Esophagus; 2009; 22(2):151-62. PubMed ID: 19021690
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo gene silencing by TransKingdom RNAi (tkRNAi).
Xiang S; Keates AC; Fruehauf J; Yang Y; Guo H; Nguyen T; Li CJ
Methods Mol Biol; 2009; 487():147-60. PubMed ID: 19301646
[TBL] [Abstract][Full Text] [Related]
15. Hydrophobic interactions between polymeric carrier and palmitic acid-conjugated siRNA improve PEGylated polyplex stability and enhance in vivo pharmacokinetics and tumor gene silencing.
Sarett SM; Werfel TA; Chandra I; Jackson MA; Kavanaugh TE; Hattaway ME; Giorgio TD; Duvall CL
Biomaterials; 2016 Aug; 97():122-32. PubMed ID: 27163624
[TBL] [Abstract][Full Text] [Related]
16. Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts.
Green DW; Roh H; Pippin JA; Drebin JA
J Surg Res; 2001 Nov; 101(1):16-20. PubMed ID: 11676549
[TBL] [Abstract][Full Text] [Related]
17. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.
Sack U; Walther W; Scudiero D; Selby M; Kobelt D; Lemm M; Fichtner I; Schlag PM; Shoemaker RH; Stein U
J Natl Cancer Inst; 2011 Jul; 103(13):1018-36. PubMed ID: 21685359
[TBL] [Abstract][Full Text] [Related]
18. Efficient Colonic Delivery of DsiRNA by Pectin-Coated Polyelectrolyte Complex Nanoparticles: Preparation, Characterization and Improved Gastric Survivability.
Hussain Z; Katas H; Yan SL; Jamaludin D
Curr Drug Deliv; 2017; 14(7):1016-1027. PubMed ID: 28240178
[TBL] [Abstract][Full Text] [Related]
19. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab.
Hart LS; Dolloff NG; Dicker DT; Koumenis C; Christensen JG; Grimberg A; El-Deiry WS
Cell Cycle; 2011 Jul; 10(14):2331-8. PubMed ID: 21720213
[TBL] [Abstract][Full Text] [Related]
20. beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model.
Ashihara E; Kawata E; Nakagawa Y; Shimazaski C; Kuroda J; Taniguchi K; Uchiyama H; Tanaka R; Yokota A; Takeuchi M; Kamitsuji Y; Inaba T; Taniwaki M; Kimura S; Maekawa T
Clin Cancer Res; 2009 Apr; 15(8):2731-8. PubMed ID: 19351774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
